Therapeutic activity of modified U1 core spliceosomal particles
Modification of the spliceosome is being tested as a potential therapy for exon-skipping diseases, such as spinal muscular atrophy (SMA). Here the authors show that 70K and stem loop IV structural elements of a modified U1 particle are essential for splicing enhancement and effective treatment of SM...
Guardado en:
Autores principales: | Malgorzata Ewa Rogalska, Mojca Tajnik, Danilo Licastro, Erica Bussani, Luca Camparini, Chiara Mattioli, Franco Pagani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b3804986740f4c778bdb533bfe47c56a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
por: Cara Lunn Shirai, et al.
Publicado: (2017) -
Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer
por: Dingxiao Zhang, et al.
Publicado: (2020) -
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
por: Hector H. Huang, et al.
Publicado: (2020) -
Gene expression profiling of U12-type spliceosome mutant Drosophila reveals widespread changes in metabolic pathways.
por: Heli K J Pessa, et al.
Publicado: (2010) -
Evolution of the Early Spliceosomal Complex—From Constitutive to Regulated Splicing
por: Sonia Borao, et al.
Publicado: (2021)